Home Pipeline

Overview

MacroGenics has a diverse portfolio of oncology product candidates with several clinical trials currently underway or planned for the near future. Set forth below is the company’s development pipeline of product candidates for which we have retained commercialization or other important rights in the U.S. or more broadly (as of April 2024).

Program (Target) Potential Indication(s) Modality Preclinical Phase 1 Phase 2 Phase 3 Partner / Sponsor
Vobramitamab Duocarmazine (B7-H3) mCRPC TAMARACK study ADC
 

NSLC, SCLC, Melanoma, SCCHN, Anal Cancer ADC
Initiation planned mid-2024

Multiple Solid Tumors (+lorigerlimab) ADC + DART®
 

Lorigerlimab (PD-1 × CTLA-4) mCRPC (+docetaxel) LORIKEET Study DART
 

Enoblituzumab (B7-H3)  Neo-adjuvant Prostate Cancer HEAT Study(a) Fc-optimized mAb
 

Tebotelimab(b) (PD-1 × LAG-3) Solid Tumors & Heme Malignancies DART
 

MGC026 (B7-H3) Multiple Solid Tumors ADC
 

MGC028 (ADAM9) Multiple Solid Tumors ADC
 

Oncology
mCRPC TAMARACK study
Modality: ADC
Preclinical Phase 1 Phase 2 Phase 3
 

NSLC, SCLC, Melanoma, SCCHN, Anal Cancer
ADC
Preclinical Phase 1 Phase 2 Phase 3
Initiation planned mid-2024

Multiple Solid Tumors (+lorigerlimab)
Modality: ADC + DART®
Preclinical Phase 1 Phase 2 Phase 3
 

Lorigerlimab (PD-1 × CTLA-4)
mCRPC (+docetaxel) LORIKEET Study
Modality: DART
Preclinical Phase 1 Phase 2 Phase 3
 

Neo-adjuvant Prostate Cancer HEAT Study(a)
Modality: Fc-optimized mAb
Preclinical Phase 1 Phase 2 Phase 3
 

Partner / Sponsor

Tebotelimab(b) (PD-1 × LAG-3)
Solid Tumors & Heme Malignancies
Modality: DART
Preclinical Phase 1 Phase 2 Phase 3
 

MGC026 (B7-H3)
Multiple Solid Tumors
Modality: ADC
Preclinical Phase 1 Phase 2 Phase 3
 

MGC028 (ADAM9)
Multiple Solid Tumors
Modality: ADC
Preclinical Phase 1 Phase 2 Phase 3
 

Partnered Programs

In addition to the molecules identified above, MacroGenics has out-licensed various product candidates for which it retains certain economic rights. These molecules provide potential sources of future cash flow and platform validation and are identified below.

Program (Target) Potential Indication(s) Modality Preclinical Phase 1 Phase 2 Phase 3 Marketed Partner
MARGENZA® (HER2)  HER2+ Metastatic Breast Cancer Fc-optimized mAb
 

Eversana logo(c)
ZYNYZ® (PD-1)  Merkel Cell Carcinoma mAb
 

Incyte logo
Squamous Cell Anal Carcinoma mAb

NSCLC mAb

TZIELD® (CD3) Stage 2 “At Risk” T1D mAb
 

Sanofi logo
Stage 3 “Early Onset” T1D mAb
 

PRV-3279 (CD32B × CD79B)  Systemic Lupus Erythematosus DART
 

Sanofi logo
MGD024 (CD123 × CD3)  CD123+ Heme Malignancies DART
 

Exclusive OptionGilead logo
Bispecific (Undisclosed) Multiple Solid Tumors DART/TRIDENT®
 

Gilead logo

MARGENZA® (HER2) 
HER2+ Metastatic Breast Cancer
Modality: Fc-optimized mAb
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Partner / Sponsor

Eversana logo(c)

ZYNYZ (PD-1) 
Merkel Cell Carcinoma
Modality: mAb
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Partner / Sponsor

Incyte logo

Squamous Cell Anal Carcinoma
Modality: mAb
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Partner / Sponsor

Incyte logo

NSCLC
Modality: mAb
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Partner / Sponsor

Incyte logo

TZIELD® (CD3)
Stage 2 “At Risk” T1D
Modality: mAb
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Stage 3 “Early Onset” T1D
Modality: mAb
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Partner / Sponsor

Sanofi logo

PRV-3279 (CD32B × CD79B) 
Systemic Lupus Erythematosus
Modality: DART
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Partner / Sponsor

Sanofi logo

MGD024 (CD123 × CD3) 
CD123+ Heme Malignancies
Modality: DART
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Partner / Sponsor

Exclusive OptionGilead logo

Bispecific (Undisclosed)
Multiple Solid Tumors
Modality: DART/TRIDENT®
Preclinical Phase 1 Phase 2 Phase 3 Marketed
 

Partner / Sponsor

Gilead logo

MGD = DART MGC = ADC
The safety and efficacy of investigational agents and/or investigational uses of approved products have not been established. Pipeline reflects current status of each program or most recently completed phase of development.

  1. The “Help Elucidate & Attack Longitudinally” (HEAT) study is an investigator-sponsored trial.
  2. MacroGenics currently has no active/ongoing tebotelimab studies.
  3. MacroGenics entered risk-sharing collaboration with Eversana in November 2020, under which MacroGenics books U.S. sales and Eversana leads execution of U.S. commercialization of MARGENZA. For all other currently partnered programs for which a license option has been exercised, the partner would book any future worldwide sales, if approved, and MacroGenics would be entitled to receive milestones and royalties.

Please note – you will leave a website owned by MacroGenics, Inc.

MacroGenics is not responsible for any content on the third party website.

Ok Close